References
- Zorzela L, Golder S, Liu Y, et al. Quality of reporting in systematic reviews of adverse events: systematic review. BMJ 2014;348:f7668
- Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions version 5.1.0. Updated March 2011. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org [Last accessed June 2017]
- Bennett C, Nebeker J, Yarnold P, et al. Evaluation of serious adverse drug reactions. A proactive pharmacovigilance program (RADAR) vs safety activities conducted by the food and drug administration and pharmaceutical manufacturers. Arch Intern Med 2007;167:1041-9
- Weaver J, Willy M, Avigan M. Informatic tools and approaches in postmarketing pharmacovigilance used by FDA. AAPS Journal 2008;10:35-41
- Hauben M, Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discovery Today 2009;14:343-57
- Allan M. A primer of drug safety surveillance: an industry perspective part III: managing adverse-event data. Pharm Technol 1992;8:259-73
- Murty M. Postmarket surveillance of natural health products in Canada: clinical and federal regulatory perspectives. Can J Physiol Pharmacol 2007;85:952-5
- van Manen RP, Fram D, DuMouchel W. Signal detection methodologies to support effective safety management. Expert Opin Drug Saf 2007;6:451-64
- Vohra S, Cvijovic K, Boon H, et al. Study of natural health product adverse reactions (SONAR): active surveillance of adverse events following concurrent natural health product and prescription drug use in community pharmacies. PLoS One 2012;7:e45196
- Zorzela L, Boon H, Mior S, et al. Serious adverse events associated with pediatric complementary and alternative medicine. Eur J Integr Med 2014;6:467-72
- Canadian Pediatric Surveillance Program. Available at: http://www.cpsp.cps.ca/about-apropos [Last accessed January 2016]
- Doherty M. Algorithms for assessing the probability of an adverse drug reaction. Respir Med CME 2009;2:63-7
- Khan L, Al-Harthi S, Osman AM, et al. Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactions. Saudi Pharmaceut J 2016;24:485-93
- Cancer therapy evaluation program, common terminology criteria for adverse events, version 4.0. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40 [Last accessed June 2016]
- World Health Organization. Available at: www.whoumc.org [Last accessed May 2017]
- The use of the WHO-UMC system for standardised case causality assessment. Available at: http://who-umc.org/Graphics/24734.pdf [Last accessed May 2017]
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45
- Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674-80
- Oxford Centre for Evidence-Based Medicine, January 2016. Available at: http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009 [Last accessed January 2016]
- Mokkink LB, Terwee CB, Knol DL, et al. The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. BMC Med Res Methodol 2010;10:22
- Scholtes V, Terwee CB, Poolman R. What makes a measurement instrument valid and reliable? Injury Int J Care Injured 2011;42:236-40
- Ide K, Yamada H, Kitagawa M, et al. Methods for estimating causal relationships of adverse events with dietary supplements. BMJ Open 2015;5:e009038
- Khan A, Adil M, Nematullah K, et al. Causality assessment of adverse drug reaction in pulmonology department of a tertiary care hospital. J Basic Clin Pharm 2015;6:84-8
- Williams E, Pahud B, Vellozzi C, et al. Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination. Vaccine 2011;29:8302-8